In her paper, van Birgelen (1) argued that hexachlorobenzene (HCB) should be dassified as a dioxin-like compound, with a toxic equivalency factor (TEF) value of 0.0001. By doing this, HCB could add 10-60% to the total toxic equivalents (TEQs) in human milk samples in most countries. To indude a compound in the TEF concept, the following criteria are used: a) the compound must show a structural relation-ship to polychlorinated dibenzo-p-dioxins or polychlorinated dibenzofurans; b) the compound must bind to the aryl hydrocarbon (Ah) receptor; c) the compound must elicit Ah receptor-mediated biochemical and toxic responses; and d) the compound must be persistent and accumulate in the food chain (2). van Birgelen (1) also referred to these criteria.
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In respect to the toxic responses, one can question the validity of using a TEF approach for HCB, because the most basic assumption for this concept is that the combined effects are dose or concentration additive (3). The dioxin-like effects for HCB mentioned by van (1) .
Because HCB also has other properties, such as being a mixed-type cytochrome P450 inducer, effects that are not typical for TCDD are to be expected. Mono-ortho-substituted polychlorinated biphenyls (PCBs) are also mixed-type cytochrome P450 inducers; they have biologic effects that differ from those produced by TCDD, and yet they are included in the TEF concept. These PCBs induce both cytochrome P4501A and P4502B activities, which are also induced by HCB. Since mono-ortho-substituted PCBs are included in the TEF concept, HCB should also be included.
However, the database used to derive a TEF value for HCB is rather weak because there are currently no in vivo data that compare HCB to TCDD. In order to produce these data, the National Toxicology Program (NTP) has initiated subchronic studies that can be used to derive in vivo relative potency values. These studies will include measurement of the activities of cytochrome P4501A1 and P4501A2, and determination of tissue concentrations to estimate the total body burden. In addition, the NTP has initiated a continuous breeding reproduction study which indudes end points that have been shown to be affected by TCDD and that currently drive risk assessment of dioxin-like compounds (3). This information should be useful in deriving a tolerable daily intake for HCB.
In conclusion, a TEF value for HCB is warranted on the basis of properties that are similar to other compounds which are included in the TEF concept. This TEF value should be based on in vivo studies to be most useful in the estimation of the total TEQ in human and environmental samples. By excluding HCB from the TEF concept, the total dioxin activity in human and environmental samples would be underestimated, especially in human breast milk (1).
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